![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Tenofovir DF (TDF) in Chronic Hepatitis B Virus Infected Patients With Documented Lamivudine Resistance (LAM-R)
|
|
|
Reported by Jules Levin
APASL 2013, Singapore
Scott Fung1, Peter Kwan,2 Andrzej Horban3, Mijomir Pelemis4, Petr Husa5, Hie-Won Hann6, John F. Flaherty7, Benedetta Massetto7, Phillip Dinh7, Amoreena Corsa7, Kathryn Kitrinos7, John G. McHutchison7, Milotka Fabri8, Edward Gane9
1Toronto General Hospital, Toronto, Ontario, Canada; 2University of British Columbia, Vancouver, BC, Canada; 3Medical University of Warsaw, Warsaw, Poland; 4Clinic for Infectious and Tropical Diseases, Belgrade, Serbia;
5Faculty Hospital Brno and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic, 6Thomas Jefferson University, Philadelphia, PA, USA; 7Gilead Sciences, Inc., Foster City, CA, USA; 8Clinic for Infectious Diseases, Novi Sad, Serbia; 9Auckland General Hospital, Auckland, New Zealand
![APASL1.gif](../images/0061213/061213-3/APASL1.gif)
![APASL2.gif](../images/0061213/061213-3/APASL2.gif)
![APASL3.gif](../images/0061213/061213-3/APASL3.gif)
![APASL4.gif](../images/0061213/061213-3/APASL4.gif)
![APASL5.gif](../images/0061213/061213-3/APASL5.gif)
![APASL6.gif](../images/0061213/061213-3/APASL6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|